UBS analyst Kevin Caliendo’s revised price target implies 15% upside ahead for shares of the health care benefit and pharmacy chain.
UBS upgrades CVS to buy rating, sees further recovery ahead
About the author
BREAKING NEWS
- ‘Coolcations’ are booming again as tourists prioritize quieter, off-peak trips
- European markets set to open higher amid positive reaction to Trump-Zelenskyy talks
- Democratic Texas lawmaker spending night on state House floor after refusing GOP demand for law enforcement escort
- Tiny worms found in ponds and river could help treat schizophrenia
- From dumpling-making to pub quizzes: Gen Z’s recipe to making friends in real life
- U.S. spy chief Gabbard says UK agreed to drop ‘back door’ mandate for Apple
